The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic Cancers

Floor J. Backes, MD
Published Online: 2:04 AM, Mon March 18, 2019

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.

Backes also noted another exciting benefit seen in this trial, the combination had good activity in both endometrial and ovarian cancer. Response rates were as high as 71% in ovarian cancer and 50% in endometrial cancers. Overall, this was only a small phase I study and needs to be confirmed in a large scale trial.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.